FDA's ARC Program Annual Report 2024: Driving Innovation in Rare Disease Drug Treatments

On Oct. 15, the FDA’s Center for Drug Evaluation and Research (CDER) released the 2024 Accelerating Rare disease Cures (ARC) Program Annual Report. Since its launch in 2022, CDER’s ARC Program has become a key resource for the rare disease community and a driver of innovation in rare disease drug treatments.

Having built a strong foundation, the ARC Program is enthusiastic about the upcoming year as it continues to strengthen collaboration to accomplish even more progress in rare disease drug development. 

To learn more about the ARC Program, its accomplishments in 2024, and the future outlook of the program, please visit Accelerating Rare disease Cures (ARC) Program Annual Report: Driving Innovation through Scientific and Regulatory Advancement.